ArticleBMC cancer2025
Unveiling GDF15 as a promising biomarker for predicting survival in pancreatic ductal carcinoma: a retrospective research.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe prognosis of pancreatic ductal adenocarcinoma remains dismal, largely because this disease is typically diagnosed at an advanced stage, making early detection a major challenge. Beyond the conventional biomarker CA19-9, emerging evidence suggests the utility of additional markers for distinguishing PDAC from normal pancreatic tissue or chronic pancreatitis. Among these, Growth Differentiation Factor 15 (GDF15), implicated in various malignancies, has arisen as a promising candidate, particularly when expressed at elevated levels in pancreatic cancer. Recent insights into the oncogenic potential of GDF15 underscore its prognostic significance.
methodsIn this study, a comprehensive analysis was performed by integrating clinicopathological data with GDF15 expression profiles from a retrospective clinical cohort. Immunohistochemical staining was used to quantify GDF15 expression in tissue samples, and expression levels were stratified using a prognosis-oriented threshold. Kaplan-Meier survival analysis was conducted to evaluate its association with overall survival.
resultsGDF15 was found to be markedly overexpressed in PDAC tissues relative to adjacent normal pancreas, supporting its potential role in promoting tumor development. In addition, high GDF15 levels were significantly linked to unfavorable clinical outcomes, underscoring its value as a prognostic indicator in pancreatic cancer.
conclusionsThe findings contribute novel insights into the role of GDF15, reinforcing its potential as a valuable prognostic biomarker for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.